Drug
Fitusiran clinical trials
Also written SAR439774.
Keep track of what changes. Save the fitusiran studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses fitusiran is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BRecruitingPhase 3SanofiNCT07285460Written as Fitusiran
- A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With EmicizumabRecruitingPhase 4SanofiNCT06145373Written as Fitusiran (SAR439774)
- Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXCompletedPhase 3Genzyme, a Sanofi CompanyNCT03754790Written as Fitusiran
- Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or BCompletedPhase 2/3Genzyme, a Sanofi CompanyNCT03974113Written as Fitusiran
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe HemophiliaActive, not recruitingPhase 3SanofiNCT05662319Written as Fitusiran
- An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or BCompletedPhase 1/2Genzyme, a Sanofi CompanyNCT02554773Written as Fitusiran (SAR439774)
- A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent ProphylaxisCompletedPhase 3Genzyme, a Sanofi CompanyNCT03549871Written as Fitusiran
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsCompletedPhase 3Genzyme, a Sanofi CompanyNCT03417102Written as fitusiran
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsCompletedPhase 3Genzyme, a Sanofi CompanyNCT03417245Written as fitusiran
- A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B PatientsCompletedPhase 1SanofiNCT02035605Written as ALN-AT3SC
Codes
What other systems call fitusiran · ClinicalTrials.gg INT001136
- MeSH (NLM) C000632624fitusiranConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) SV9W47ZLE1FITUSIRANConfirmed FDA, NLM
- NCI Thesaurus C169984FitusiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632624 | fitusiran | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | SV9W47ZLE1 | FITUSIRAN | Confirmed FDA, NLM |
| NCI Thesaurus | C169984 | Fitusiran | One source FDA |
Also registered as fitusiran sodium (UNII A2PQ8BS44A).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.